Home LiteratureArticle Details
PMID: 10496354 Published · ppublish English Journal Article

Proteolysis in human breast and colorectal cancer.

British journal of cancer ·Vol. 81 ·No. 2 ·1999-09-00 ·Pages 287-93

Garbett EA, Reed MW, Brown NJ

Abstract

Proteolysis occurs when proteinase activity exceeds inhibitor activity. Proteolysis is normally tightly regulated and is involved in cancer invasion and metastasis. The aim of this study was to compare proteolysis in breast and colorectal cancer. Proteinase and inhibitor expression were analysed in paired tumour and normal tissue samples from 43 breast and 24 colorectal cancer patients using substrate zymography, Western blotting and quenched fluorescence substrate hydrolysis. The expression of the latent forms of matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-9, urokinase plasminogen activator (uPA), tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression were observed in both tumour and normal tissue samples from breast and colorectal tissue; however, expression was greater in the tumour tissue. Expression of active MMP-2 and MMP-9 and the total MMP activity were greater in tumour compared to normal samples in both tissues (P < 0.05). The expression of all proteinases and total MMP activity was greater in colorectal tissue than breast tissue samples. Breast and colorectal cancer demonstrated different proteinase profiles, however proteolysis in both tissues was greater in tumour tissue than normal tissue.

MeSH Terms
Blotting, Western Breast Neoplasms/metabolism,pathology Colorectal Neoplasms/metabolism,pathology Extracellular Matrix/metabolism Fluorescence Humans Metalloendopeptidases/metabolism Neoplasm Invasiveness Neoplasm Metastasis Tissue Inhibitor of Metalloproteinases/metabolism Tumor Cells, Cultured
Chemicals
Tissue Inhibitor of Metalloproteinases Metalloendopeptidases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Garbett E A
Professional Unit of Surgery, North Tees General Hospital, Stockton-on-Tees, UK.
Reed M W
Brown N J
References (37)
37 references, click to expand
  1. Plasma concentration of matrix metalloproteinase 9 in gastric cancer.
    Br J Surg. 1997 Jan;84(1):133-6 PMID: 9043478
  2. Matrix-degrading metalloproteinases in tumor progression.
    Princess Takamatsu Symp. 1994;24:152-61 PMID: 8983072
  3. The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor.
    Biochem J. 1983 May 1;211(2):313-8 PMID: 6307277
  4. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
    Br J Cancer. 1998 Mar;77(6):926-31 PMID: 9528836
  5. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
    Semin Thromb Hemost. 1991 Jul;17(3):303-12 PMID: 1796300
  6. MMP-2: expression, activation and inhibition.
    Enzyme Protein. 1996;49(1-3):7-19 PMID: 8796994
  7. Classification of peptidases.
    Methods Enzymol. 1994;244:1-15 PMID: 7845199
  8. Expression of activated gelatinase in human invasive breast carcinoma.
    Clin Exp Metastasis. 1993 Mar;11(2):183-9 PMID: 8444010
  9. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology.
    Invasion Metastasis. 1993;13(1):31-7 PMID: 8407209
  10. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
    Am J Pathol. 1991 May;138(5):1059-67 PMID: 1850957
  11. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Br J Cancer. 1994 Feb;69(2):398-405 PMID: 8297742
  12. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy.
    Br J Cancer. 1998 Dec;78(11):1495-502 PMID: 9836483
  13. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.
    FEBS Lett. 1992 Jan 27;296(3):263-6 PMID: 1537400
  14. Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines.
    Br J Cancer. 1997;75(7):951-9 PMID: 9083329
  15. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology.
    Bull Cancer. 1992;79(3):261-70 PMID: 1392165
  16. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
    Hum Pathol. 1995 Oct;26(10):1133-8 PMID: 7557947
  17. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis.
    Clin Exp Metastasis. 1996 Mar;14(2):115-24 PMID: 8605725
  18. Electrophoretic analysis of proteins associated with tumor cell invasion.
    Electrophoresis. 1994 Mar-Apr;15(3-4):454-62 PMID: 8055871
  19. Urokinase plasminogen activator and prognosis in breast cancer.
    Lancet. 1990 Jan 13;335(8681):108 PMID: 1967386
  20. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Drugs Aging. 1997 Sep;11(3):229-44 PMID: 9303281
  21. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours.
    Int J Cancer. 1991 Nov 11;49(5):666-72 PMID: 1657796
  22. The plasminogen-plasmin system in malignancy.
    Cancer Metastasis Rev. 1992 Nov;11(3-4):291-311 PMID: 1423820
  23. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
    Am J Pathol. 1991 Jan;138(1):111-7 PMID: 1702928
  24. Matrix metalloproteinase family.
    Cell Biol Int. 1995 Mar;19(3):239-42 PMID: 7606234
  25. Utilization of transgenic mice in the study of matrix degrading proteinases and their inhibitors.
    Cancer Metastasis Rev. 1995 Jun;14(2):97-111 PMID: 7554034
  26. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
    Surg Oncol. 1995;4(2):111-9 PMID: 7551259
  27. Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity.
    Clin Mol Pathol. 1996 Dec;49(6):M331-9 PMID: 16696099
  28. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer.
    Cancer Res. 1996 Jan 1;56(1):190-6 PMID: 8548762
  29. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response.
    Am J Pathol. 1996 Jul;149(1):273-82 PMID: 8686751
  30. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.
    Br J Cancer. 1994 Jan;69(1):177-82 PMID: 7506923
  31. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates.
    Anal Biochem. 1980 Feb;102(1):196-202 PMID: 7188842
  32. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer.
    Nat Med. 1996 Apr;2(4):461-2 PMID: 8597958
  33. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
    Cancer Metastasis Rev. 1990 Dec;9(4):353-67 PMID: 2129023
  34. Activity of type IV collagenases in benign and malignant breast disease.
    Br J Cancer. 1993 May;67(5):1126-31 PMID: 8494711
  35. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
    Breast Cancer Res Treat. 1993;24(3):195-208 PMID: 8435475
  36. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
    J Natl Cancer Inst. 1995 Feb 15;87(4):293-8 PMID: 7535861
  37. Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.
    Biomed Biochim Acta. 1991;50(4-6):731-41 PMID: 1801751
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/sj.bjc.6690689
Published
1999-09-00
Pages
287-93
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2362855
Subset
IM
External Links
PubMed source DOI: 10.1038/sj.bjc.6690689 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2